LE WE PMID CA
Endocannabinoid790Endocannabinoid

2 Arachidonoylglycerol

Addiction (BASKET)

Adiponectin

AMP activated protein kinase

Anandamide

Antiinflammatory compounds

Arachidonoyl dopamine

Arachidonoyl serotonin

Arachidonoyl vanillic acid ttTRPV1

Arachidonoyldiacylglycerol

Arachidonylethanolamide

beta oxidation

Bimatoprost

Bone (Physiology)

Cannabis

Cardiovascular risk

CaV3 1

CaV3 2

CaV3 3

COX2

CP55940 ttCB

Cyclooxygenases

Depression

Docosahexaenoic acid

Embryology (BASKET)

Endocannabinoid

Endovanilloid

Evolution

Eye (Glaucoma)

Fatty acid amide hydrolase

Fatty acids (Biosynthesis)

Fatty acids (oxidation)

Fibrosis

Genetics (Selective sweep)

Ghrelin

Glucocorticoids

Gluconeogenesis

Glyceryl prostaglandins

Glycogen

Glycolysis

GPR55

Heart (Physiology)

Insulin (BASKET)

Ion channel (Calcium T Type)

Ischemia reperfusion

JWH133

Leptin

Lipid rafts and membrane microdomains

Liver (Steatohepatosis)

Metformin

Microdialysis

Mitochondria (BASKET)

N arachidonoyl dopamine

N arachidonoyl glycine

Natural products

Neuromedin U

Neuron (BASKET)

Neuropeptide Y

Neuroprotective agents

Nutrition (Neuroendocrinology)

Obesity (BASKET)

PAF

Pain (Neurophysiology)

Periaquaeductal gray

Phobia (Neurophysiology)

Prefrontal cortex

Prostamid

Receptor (Cannabinoid)

Receptor (PPAR)

Reward (Neurophysiology)

Rimonabant

Skin (Pathology)

Stress (Neurophysiology)

Thiazolidinediones

Virodhamine

2008  
1
The endocannabinoid system: an osteopathic perspective.
[18948642] J Am Osteopath Assoc 108(10): 586-600 (2008)
2007  
2
The endocannabinoid system as a novel approach for managing obesity.
[17784530] J Am Osteopath Assoc 107(4 Suppl 2): S12-20 (2007)
2005  
3
Interactions between cannabinoid and opioid receptor systems in the mediation of ethanol effects.
[15550451] Alcohol Alcohol 40(1): 25-34 (2005)
2005  
4
The endocannabinoid system: physiology and pharmacology.
[15550444] Alcohol Alcohol 40(1): 2-14 (2005)
2005  
5
Role of the endocannabinoid system in the development of tolerance to alcohol.
[15550443] Alcohol Alcohol 40(1): 15-24 (2005)
2007  
6
Modulation of fear and anxiety by the endogenous cannabinoid system.
[17329982] CNS Spectr 12(3): 211-20 (2007)
2007  
7
Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity.
[18084639] Curr Neuropharmacol 5(2): 81-97 (2007)
2009  
8
The endocannabinoid system as a target for the treatment of motor dysfunction.
[19220290] Br J Pharmacol 156(7): 1029-40 (2009)
2009  
9
Emerging strategies for exploiting cannabinoid receptor agonists as medicines.
[19226257] Br J Pharmacol 156(3): 397-411 (2009)
2008  
10
The endocannabinoid system in brain reward processes.
[18414385] Br J Pharmacol 154(2): 369-83 (2008)
2008  
11
CB2 receptors in the brain: role in central immune function.
[18037916] Br J Pharmacol 153(2): 240-51 (2008)
2008  
12
Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.
[18026124] Br J Pharmacol 153(2): 252-62 (2008)
2008  
13
Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain.
[17994113] Br J Pharmacol 153(2): 319-34 (2008)
2008  
14
The peripheral cannabinoid receptor knockout mice: an update.
[17965741] Br J Pharmacol 153(2): 309-18 (2008)
2008  
15
Cannabinoid CB2 receptors in human brain inflammation.
[17934510] Br J Pharmacol 153(2): 277-85 (2008)
2008  
16
Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor.
[17922025] Br J Pharmacol 153(2): 271-6 (2008)
2008  
17
Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists.
[17906679] Br J Pharmacol 153(2): 226-39 (2008)
2008  
18
Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation.
[17906675] Br J Pharmacol 153(2): 263-70 (2008)
2008  
19
CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies.
[17891163] Br J Pharmacol 153(2): 216-25 (2008)
2008  
20
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
[17828291] Br J Pharmacol 153(2): 199-215 (2008)
2008  
21
2007  
22
2007  
23
Cannabinoid control of neuroinflammation related to multiple sclerosis.
[17891167] Br J Pharmacol 152(5): 649-54 (2007)
2007  
24
The complications of promiscuity: endocannabinoid action and metabolism.
[17876303] Br J Pharmacol 152(5): 602-23 (2007)
2007  
25
Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate.
[17828292] Br J Pharmacol 152(5): 633-48 (2007)
2007  
26
Endocannabinoids and the gastrointestinal tract: what are the key questions?
[17767170] Br J Pharmacol 152(5): 663-70 (2007)
2007  
27
Endocannabinoids and the haematological system.
[17704826] Br J Pharmacol 152(5): 671-5 (2007)
2007  
28
Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors.
[17704824] Br J Pharmacol 152(5): 576-82 (2007)
2007  
29
Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain.
[17704819] Br J Pharmacol 152(5): 624-32 (2007)
2007  
30
The contribution of cyclooxygenase-2 to endocannabinoid metabolism and action.
[17618306] Br J Pharmacol 152(5): 594-601 (2007)
2007  
31
Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions.
[17450170] Br J Pharmacol 151(4): 427-40 (2007)
2005  
32
The expanding field of cannabimimetic and related lipid mediators.
[15655504] Br J Pharmacol 144(4): 459-65 (2005)
2004  
33
Efficacy in CB1 receptor-mediated signal transduction.
[15308578] Br J Pharmacol 142(8): 1209-18 (2004)
2004  
34
The complexities of the cardiovascular actions of cannabinoids.
[15131000] Br J Pharmacol 142(1): 20-6 (2004)
2004  
35
Endocannabinoid-mediated short-term synaptic plasticity: depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE).
[15100161] Br J Pharmacol 142(1): 9-19 (2004)
2004  
36
Involvement of cannabinoid receptors in gut motility and visceral perception.
[15100166] Br J Pharmacol 141(8): 1335-45 (2004)
2004  
37
Cannabinoids and neuroinflammation.
[14757702] Br J Pharmacol 141(5): 775-85 (2004)
2004  
38
The endocannabinoid system: a general view and latest additions.
[14744801] Br J Pharmacol 141(5): 765-74 (2004)
2003  
39
Emerging roles for endocannabinoids in long-term synaptic plasticity.
[14504143] Br J Pharmacol 140(5): 781-9 (2003)
2003  
40
Endocannabinoids as mediators in the heart: a potential target for therapy of remodelling after myocardial infarction?
[12711614] Br J Pharmacol 138(7): 1183-4 (2003)
2001  
41
Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology.
[11408519] J Pharmacol Exp Ther 298(1): 7-14 (2001)
2000  
42
Endocannabinoids and vascular function.
[10871291] J Pharmacol Exp Ther 294(1): 27-32 (2000)
2006  
43
The endocannabinoid system as an emerging target of pharmacotherapy.
[16968947] Pharmacol Rev 58(3): 389-462 (2006)
2003  
44
The cannabinoid system and immune modulation.
[12960289] J Leukoc Biol 74(4): 486-96 (2003)
2007  
45
Cannabinoids: a new group of agonists of PPARs.
[18288264] PPAR Res 2007(-): 23513 (2007)
2005  
46
Review article: endocannabinoids and their receptors in the enteric nervous system.
[16197488] Aliment Pharmacol Ther 22(8): 667-83 (2005)
2009  
47
Endocannabinoid-mediated control of synaptic transmission.
[19126760] Physiol Rev 89(1): 309-80 (2009)
2003  
48
Role of endogenous cannabinoids in synaptic signaling.
[12843414] Physiol Rev 83(3): 1017-66 (2003)
2006  
49
The emerging role of the endocannabinoid system in endocrine regulation and energy balance.
[16306385] Endocr Rev 27(1): 73-100 (2006)
2005  
50
Endocannabinoids and food intake: newborn suckling and appetite regulation in adulthood.
[15792943] Exp Biol Med (Maywood) 230(4): 225-34 (2005)
2005  
51
Neurotransmission: emerging roles of endocannabinoids.
[16051162] Curr Biol 15(14): R549-51 (2005)
2007  
52
Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients.
[17418607] Diabetes Metab 33(2): 85-95 (2007)
2007  
53
Integrated physiology and pathophysiology of CB1-mediated effects of the endocannabinoid system.
[17350871] Diabetes Metab 33(2): 97-107 (2007)
2008  
54
Endocannabinoids in endocrine and related tumours.
[18508995] Endocr Relat Cancer 15(2): 391-408 (2008)
2009  
55
Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists.
[19729432] Eur J Endocrinol 161(5): 655-62 (2009)
2001  
56
Cannabinoids and the gastrointestinal tract.
[11358910] Gut 48(6): 859-67 (2001)
2008  
57
Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations.
[18779440] Hypertension 52(4): 601-7 (2008)
2010  
58
Role of cannabinoids in the development of fatty liver (steatosis).
[20204561] AAPS J 12(2): 233-7 (2010)
2009  
59
Cannabinoids, endocannabinoids, and related analogs in inflammation.
[19199042] AAPS J 11(1): 109-19 (2009)
2005  
60
Further advances in the synthesis of endocannabinoid-related ligands.
[16353927] AAPS J 7(2): E496-502 (2005)
2005  
61
The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.
[16353941] AAPS J 7(3): E625-54 (2005)
2008  
62
Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver.
[17975129] Am J Physiol Gastrointest Liver Physiol 294(1): G9-G12 (2008)
2008  
63
Endocannabinoids and liver disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis.
[18006606] Am J Physiol Gastrointest Liver Physiol 294(2): G357-62 (2008)
2008  
64
Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases.
[18239059] Am J Physiol Gastrointest Liver Physiol 294(4): G850-4 (2008)
2008  
65
Pleiotropic effects of the CB2 cannabinoid receptor activation on human monocyte migration: implications for atherosclerosis and inflammatory diseases.
[18203843] Am J Physiol Heart Circ Physiol 294(3): H1133-4 (2008)
2008  
66
Non-redundant functions of cyclooxygenases: oxygenation of endocannabinoids.
[18250160] J Biol Chem 283(13): 8065-9 (2008)
2002  
67
2011  
68
Cannabinoids and innate immunity: taking a toll on neuroinflammation.
[21479354] ScientificWorldJournal 11(-): 855-65 (2011)
2003  
69
Synaptic lipid signaling: significance of polyunsaturated fatty acids and platelet-activating factor.
[13130128] J Lipid Res 44(12): 2221-33 (2003)
2008  
70
Cannabinoids as therapeutic agents for ablating neuroinflammatory disease.
[18782012] Endocr Metab Immune Disord Drug Targets 8(3): 159-72 (2008)
2006  
71
Signaling pathways involved in the cardioprotective effects of cannabinoids.
[17031075] J Pharmacol Sci 102(2): 155-66 (2006)
2010  
72
Endocannabinoid signalling: has it got rhythm?
[20590563] Br J Pharmacol 160(3): 530-43 (2010)
2010  
73
Phytocannabinoids beyond the Cannabis plant - do they exist?
[20590562] Br J Pharmacol 160(3): 523-9 (2010)
2010  
74
The endocannabinoid system as a target for the treatment of neurodegenerative disease.
[20590559] Br J Pharmacol 160(3): 480-98 (2010)
2010  
75
CB2: a cannabinoid receptor with an identity crisis.
[20590558] Br J Pharmacol 160(3): 467-79 (2010)
2010  
76
Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls.
[20590555] Br J Pharmacol 160(3): 423-42 (2010)
2008  
77
Prostamides (prostaglandin-ethanolamides) and their pharmacology.
[17721551] Br J Pharmacol 153(3): 410-9 (2008)
2008  
78
Cannabinoids for cancer treatment: progress and promise.
[18199524] Cancer Res 68(2): 339-42 (2008)
2006  
79
Endocannabinoids--the brain's own marijuana--may be linked to the metabolic syndrome.
[17415289] MedGenMed 8(4): 7 (2006)
2007  
80
Serotonin, the prefrontal cortex, and the antidepressant-like effect of cannabinoids.
[18057193] J Neurosci 27(49): 13369-70 (2007)
2006  
81
The endocannabinoid system: a new perspective for cardiometabolic risk control.
[17128328] Arq Bras Cardiol 87(4): 548-58 (2006)
2008  
82
2008  
83
Aspects of endocannabinoid signaling in periimplantation biology.
[18294762] Mol Cell Endocrinol 286(1-2 Suppl 1): S3-11 (2008)
2010  
84
Pharmacological characterization of GPR55, a putative cannabinoid receptor.
[20298715] Pharmacol Ther 126(3): 301-13 (2010)
2009  
85
Minireview: Endocannabinoids and their receptors as targets for obesity therapy.
[19372200] Endocrinology 150(6): 2531-6 (2009)
2007  
86
Role of endocannabinoids in regulating drug dependence.
[19300605] Neuropsychiatr Dis Treat 3(6): 711-21 (2007)
2009  
87
Inhibition of human recombinant T-type calcium channels by the endocannabinoid N-arachidonoyl dopamine.
[19226289] Br J Pharmacol 156(5): 740-50 (2009)
2010  
88
A putative 'pre-nervous' endocannabinoid system in early echinoderm development.
[19907129] Dev Neurosci 32(1): 1-18 (2010)
2009  
89
Localization of the endocannabinoid-degrading enzyme fatty acid amide hydrolase in rat dorsal root ganglion cells and its regulation after peripheral nerve injury.
[19321773] J Neurosci 29(12): 3766-80 (2009)
2006  
90
Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors.
[16284279] J Pharmacol Exp Ther 316(3): 969-82 (2006)
2007  
91
Tempo and mode in the endocannaboinoid system.
[17676365] J Mol Evol 65(3): 267-76 (2007)
2009  
92
(Endo)cannabinoids mediate different Ca2+ entry mechanisms in human bronchial epithelial cells.
[19255745] Naunyn Schmiedebergs Arch Pharmacol 380(1): 67-77 (2009)
2009  
93
The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities.
[19608284] Trends Pharmacol Sci 30(8): 411-20 (2009)
2010  
94
Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications.
[20133390] Pharmacol Rev 62(1): 136-54 (2010)
2009  
95
The endocannabinoid system: potential for reducing cardiometabolic risk.
[19373218] Obesity (Silver Spring) 17(10): 1821-9 (2009)
2008  
96
Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties.
[18076956] Physiol Behav 93(4-5): 666-70 (2008)
2010  
97
Understanding functional residues of the cannabinoid CB1.
[20370713] Curr Top Med Chem 10(8): 779-98 (2010)
2007  
98
Endocannabinoid system involvement in brain reward processes related to drug abuse.
[17936009] Pharmacol Res 56(5): 393-405 (2007)
2007  
99
Modulation of the endocannabinoid system: therapeutic potential against cocaine dependence.
[17945506] Pharmacol Res 56(5): 406-17 (2007)
2007  
100
Enhancement of endocannabinoid signaling and the pharmacotherapy of depression.
[17945507] Pharmacol Res 56(5): 360-6 (2007)
2009  
101
Endocannabinoids and immune regulation.
[19428268] Pharmacol Res 60(2): 85-92 (2009)
2009  
102
Endocannabinoids and cardiac contractile function: pathophysiological implications.
[19569260] Pharmacol Res 60(2): 99-106 (2009)
2009  
103
2008  
104
Glucocorticoids shift arachidonic acid metabolism toward endocannabinoid synthesis: a non-genomic anti-inflammatory switch.
[18295199] Eur J Pharmacol 583(2-3): 322-39 (2008)
2007  
105
The endocannabinoid signaling system: a potential target for next-generation therapeutics for alcoholism.
[17692039] Mini Rev Med Chem 7(8): 769-79 (2007)
2009  
106
2008  
107
Membrane microdomains and metabolic pathways that define anandamide and 2-arachidonyl glycerol biosynthesis and breakdown.
[18760289] Neuropharmacology 55(7): 1095-104 (2008)
2008  
108
The elmiric acids: biologically active anandamide analogs.
[18187165] Neuropharmacology 55(8): 1259-64 (2008)
2010  
109
Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas.
[20468046] Glia 58(9): 1017-30 (2010)
2009  
110
2010  
111
Involvement of the endocannabinoid system in the neurobehavioural effects of stress and glucocorticoids.
[19903506] Prog Neuropsychopharmacol Biol Psychiatry 34(5): 791-7 (2010)
2009  
112
The emerging role of the endocannabinoid system in cardiovascular disease.
[19357846] Semin Immunopathol 31(1): 63-77 (2009)
2010  
113
Hypothalamic regulation of bone.
[20660619] J Mol Endocrinol 45(4): 175-81 (2010)
2010  
114
AMPK as a mediator of hormonal signalling.
[19625456] J Mol Endocrinol 44(2): 87-97 (2010)
2011  
115
Endocannabinoid system in cardiovascular disorders - new pharmacotherapeutic opportunities.
[21966155] J Pharm Bioallied Sci 3(3): 350-60 (2011)
2010  
116
Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality.
[19527737] Life Sci 86(15-16): 615-23 (2010)
2011  
117
Cannabinoid system and cyclooxygenases inhibitors.
[21505570] J Med Life 4(1): 11-20 (2011)
2010  
118
In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability.
[19523530] Prostaglandins Other Lipid Mediat 91(3-4): 90-103 (2010)
2007  
119
Critical enzymes involved in endocannabinoid metabolism.
[17346227] Protein Pept Lett 14(3): 237-46 (2007)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.



  • Endocannabinoid

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia